Details of Disease

General Information of Disease (ID: DISFFVF9)

• Disease Name: Allergic contact dermatitis
• Synonyms: allergic contact dermatitis; allergic form of contact dermatitis
• Disease Class: EK00-EK0Z: Contact dermatitis
• Definition: An inflammatory skin condition caused by an immune response to direct contact between the skin and an allergen. It consists of a delayed type of allergic reaction at the affected site with resulting red, swollen, and blistered skin that may itch or leak.
• Disease Hierarchy:
  DISTCP41: Atopic dermatitis
  DISQ3AU0: Contact dermatitis
  DISFFVF9: Allergic contact dermatitis
• ICD Code:
  ICD-11: ICD-11: EK00
  Expand ICD-11: 'EK00
  Expand ICD-10: 'L23; 'L23.1; 'L23.4; 'L23.5
• Disease Identifiers:
  MONDO ID: MONDO_0006525
  MESH ID: D017449
  UMLS CUI: C0162820
  MedGen ID: 102474
  SNOMED CT ID: 238575004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BBI-2000	DMPEGES	Phase 2	NA	[1]

This Disease is Treated as An Indication in 2 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ac-YVAD-cmk	DMA1RVN	Patented	Peptide	[2]
Ac-YVAD-FMK	DM7K256	Patented	Peptide	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 39 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CCL17	TTMPHAE	Limited	Altered Expression	[3]
IL16	TTW4R0B	Limited	Altered Expression	[4]
IL18	TTRICUF	Limited	Biomarker	[5]
PLAT	TTXAGYU	Limited	Biomarker	[6]
SPP1	TT8ME6I	Limited	Biomarker	[7]
SUCNR1	TT4FX9Y	Limited	Biomarker	[8]
ASRGL1	TT4WT91	Strong	Biomarker	[9]
CASP8	TT6SZNG	Strong	Biomarker	[9]
CCR5	TTJIH8Q	Strong	Biomarker	[10]
CXCL2	TTZF0K2	Strong	Biomarker	[11]
ETS2	TT9AH0M	Strong	Biomarker	[9]
GRK2	TTAZ3MN	Strong	Biomarker	[9]
HSD11B1	TTN7BL9	Strong	Biomarker	[9]
IL2	TTF89GD	Strong	Biomarker	[12]
IL2RA	TT10Y9E	Strong	Biomarker	[9]
IL32	TTD4G7L	Strong	Biomarker	[13]
IL4	TTLGTKB	Strong	Biomarker	[14]
IL5	TTPREZD	Strong	Biomarker	[15]
ITGAM	TTB69FJ	Strong	Biomarker	[9]
KMO	TTIY56R	Strong	Biomarker	[9]
MMP3	TTUZ2L5	Strong	Biomarker	[10]
MRC1	TTKV8W5	Strong	Biomarker	[9]
NFE2L2	TTA6ZN2	Strong	Biomarker	[16]
PIM1	TTTN5QW	Strong	Biomarker	[9]
PRDX4	TTPBL9I	Strong	Biomarker	[9]
QPCT	TTJ7YTV	Strong	Biomarker	[9]
SELE	TT1PL7M	Strong	Biomarker	[13]
SOCS1	TT8COJM	Strong	Biomarker	[9]
TLR7	TTRJ1K4	Strong	Biomarker	[9]
TRPA1	TTELV3W	Strong	Biomarker	[17]
BMP6	TT07RIB	Definitive	Biomarker	[18]
CALCRL	TTY6O0Q	Definitive	Biomarker	[18]
CCR2	TTFZYTO	Definitive	Biomarker	[18]
CD36	TTPJMCU	Definitive	Biomarker	[18]
CTSC	TT4H0V2	Definitive	Biomarker	[18]
F13A1	TTXI2RA	Definitive	Biomarker	[18]
FGL2	TTYBS89	Definitive	Biomarker	[18]
NAMPT	TTD1WIG	Definitive	Biomarker	[18]
SLC7A5	TTPH2JB	Definitive	Biomarker	[18]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCA6	DTLMZUF	Definitive	Biomarker	[18]
SLC2A3	DT9SQ3L	Definitive	Biomarker	[18]

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP1A1	DE6OQ3W	Limited	Biomarker	[19]
UPP1	DEFZWAX	Strong	Biomarker	[9]
SAT1	DEMWO83	Definitive	Biomarker	[18]

This Disease Is Related to 35 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCL27	OTUZYC61	Limited	Altered Expression	[3]
CCR10	OT7ZWSSD	Limited	Altered Expression	[20]
CD1D	OT3ROU4J	Limited	Biomarker	[21]
ELOVL6	OTB26UJJ	Limited	Genetic Variation	[22]
GADD45G	OT8V1J4M	Limited	Biomarker	[23]
HRNR	OT560QR5	Limited	Biomarker	[24]
IL26	OT2WYCW4	Limited	Biomarker	[25]
LCE3B	OT7X6LDK	Limited	Genetic Variation	[22]
LCE3C	OT3RWMGH	Limited	Genetic Variation	[22]
CCL19	OTQ2UJMH	Strong	Altered Expression	[13]
CD3D	OTRBLP0R	Strong	Biomarker	[13]
CISH	OT8T5NYL	Strong	Biomarker	[9]
CNTN3	OTC1274J	Strong	Biomarker	[13]
FCGR3B	OTSLSPZG	Strong	Biomarker	[9]
FLG	OTE9QDV6	Strong	Biomarker	[26]
FYB1	OT6345CH	Strong	Biomarker	[9]
IFI30	OT9DERT1	Strong	Biomarker	[13]
IGSF6	OT5TUH02	Strong	Biomarker	[9]
MEOX1	OTJEMT2D	Strong	Biomarker	[9]
NUMA1	OTTKAVG4	Strong	Biomarker	[9]
ORM1	OTZKSBRE	Strong	Genetic Variation	[27]
SOCS2	OTBPNKJQ	Strong	Biomarker	[9]
ST6GAL1	OT7US3NO	Strong	Biomarker	[9]
STAC	OTRVBSLR	Strong	Biomarker	[9]
TMSB10	OTLVZ13T	Strong	Biomarker	[13]
CIDEC	OTMDZ56K	Definitive	Biomarker	[18]
CREM	OTJIJ5AL	Definitive	Biomarker	[18]
EMB	OT67E3Q1	Definitive	Biomarker	[18]
IPCEF1	OTOUIHID	Definitive	Biomarker	[18]
MXD1	OTS5CTHX	Definitive	Biomarker	[18]
NINJ1	OTLRZ1EU	Definitive	Biomarker	[18]
PHLDA1	OTFTWMIQ	Definitive	Biomarker	[18]
RAB32	OTTR4H7S	Definitive	Biomarker	[18]
RGS1	OTGXJYMG	Definitive	Biomarker	[18]
TNFAIP6	OT1SLUZH	Definitive	Biomarker	[18]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59.
• [3] Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis.Exp Dermatol. 2011 Oct;20(10):789-94. doi: 10.1111/j.1600-0625.2011.01323.x. Epub 2011 Jun 24.
• [4] Stratum corneum profiles of inflammatory mediators in patch test reactions to common contact allergens and sodium lauryl sulfate.Br J Dermatol. 2017 Jun;176(6):1533-1540. doi: 10.1111/bjd.15163. Epub 2017 Apr 6.
• [5] Innate immunity and effector and regulatory mechanisms involved in allergic contact dermatitis.An Bras Dermatol. 2018 Mar;93(2):242-250. doi: 10.1590/abd1806-4841.20186340.
• [6] Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models.BMC Immunol. 2013 Nov 18;14:51. doi: 10.1186/1471-2172-14-51.
• [7] Antigen-specific induction of osteopontin contributes to the chronification of allergic contact dermatitis.Am J Pathol. 2010 Jan;176(1):246-58. doi: 10.2353/ajpath.2010.090488. Epub 2009 Dec 11.
• [8] GPR91 deficiency exacerbates allergic contact dermatitis while reducing arthritic disease in mice.Allergy. 2017 Mar;72(3):444-452. doi: 10.1111/all.13005. Epub 2016 Sep 12.
• [9] Gene transcripts as potential diagnostic markers for allergic contact dermatitis.Contact Dermatitis. 2005 Aug;53(2):100-6. doi: 10.1111/j.0105-1873.2005.00658.x.
• [10] Gene expression profiling of skin and draining lymph nodes of rats affected with cutaneous contact hypersensitivity.Inflamm Res. 2006 Aug;55(8):322-34. doi: 10.1007/s00011-006-5141-z.
• [11] Differentiation of skin sensitizers from irritant chemicals by interleukin-1 and macrophage inflammatory protein-2 in murine keratinocytes.Toxicol Lett. 2013 Jan 10;216(1):65-71. doi: 10.1016/j.toxlet.2012.10.017. Epub 2012 Nov 22.
• [12] B cell increases and ex vivo IL-2 production as secondary endpoints for the detection of sensitizers in non-radioisotopic local lymph node assay using flow cytometry.Toxicol Lett. 2012 Mar 25;209(3):255-63. doi: 10.1016/j.toxlet.2011.12.012. Epub 2012 Jan 2.
• [13] Gene expression time course in the human skin during elicitation of allergic contact dermatitis.J Invest Dermatol. 2007 Nov;127(11):2585-95. doi: 10.1038/sj.jid.5700902. Epub 2007 Jun 28.
• [14] A novel animal model of pruritus induced by successive application of glucocorticoid to mouse skin.J Toxicol Sci. 2011 Aug;36(4):395-401. doi: 10.2131/jts.36.395.
• [15] Analysis of effector and regulatory immune reactivity to nickel.Clin Exp Allergy. 2004 Sep;34(9):1458-66. doi: 10.1111/j.1365-2222.2004.02045.x.
• [16] Allergic skin inflammation induced by chemical sensitizers is controlled by the transcription factor Nrf2.Toxicol Sci. 2013 Jul;134(1):39-48. doi: 10.1093/toxsci/kft084. Epub 2013 Apr 5.
• [17] TRPA1 mediated aggravation of allergic contact dermatitis induced by DINP and regulated by NF-B activation.Sci Rep. 2017 Feb 27;7:43586. doi: 10.1038/srep43586.
• [18] Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol. 2007 May;44(12):3222-33.
• [19] Relation of PON1 and CYP1A1 genetic polymorphisms to clinical findings in a cross-sectional study of a Greek rural population professionally exposed to pesticides.Toxicol Lett. 2009 Apr 10;186(1):66-72. doi: 10.1016/j.toxlet.2008.10.018. Epub 2008 Oct 28.
• [20] Increased CCL27-CCR10 expression in allergic contact dermatitis: implications for local skin memory.J Pathol. 2004 Sep;204(1):39-46. doi: 10.1002/path.1619.
• [21] CD1d-dependent, iNKT-cell cytotoxicity against keratinocytes in allergic contact dermatitis.Exp Dermatol. 2012 Dec;21(12):915-20. doi: 10.1111/exd.12036.
• [22] Deletion of the late cornified envelope genes LCE3B and LCE3C may promote chronic hand eczema with allergic contact dermatitis.J Investig Allergol Clin Immunol. 2011;21(6):472-9.
• [23] Skin application of glutathione and iron sulfate can inhibit elicitation of allergic contact dermatitis from hexavalent chromium.Contact Dermatitis. 2020 Jan;82(1):45-53. doi: 10.1111/cod.13409. Epub 2019 Nov 14.
• [24] Transient epidermal barrier deficiency and lowered allergic threshold in filaggrin-hornerin (FlgHrnr(-/-) ) double-deficient mice.Allergy. 2019 Jul;74(7):1327-1339. doi: 10.1111/all.13756. Epub 2019 Apr 15.
• [25] IL-26 in allergic contact dermatitis: Resource in a state of readiness.Exp Dermatol. 2018 Jun;27(6):681-684. doi: 10.1111/exd.13521. Epub 2018 Apr 10.
• [26] Filaggrin and atopic march.Biochem Med (Zagreb). 2019 Jun 15;29(2):020501. doi: 10.11613/BM.2019.020501.
• [27] Orosomucoid types in allergic contact dermatitis.Hum Hered. 1995 Mar-Apr;45(2):117-20. doi: 10.1159/000154269.